This clinical trial is focused on studying sickle cell disease, a genetic condition that affects the red blood cells, leading to episodes of severe pain known as vaso-occlusive crises. The study will evaluate a treatment called CSL889, which is a form of hemopexin, human, a protein that may help manage these painful episodes. The treatment is given as a solution through an intravenous infusion, meaning it is delivered directly into the bloodstream through a vein.
The purpose of the study is to assess the safety and effectiveness of CSL889 in helping to resolve vaso-occlusive crises in people with sickle cell disease. Participants in the study will receive either the CSL889 treatment or a placebo, which is a solution that does not contain the active substance. The study will monitor how quickly the painful episodes resolve and will also track any side effects that may occur.
Participants will be involved in the study for a period of time during which they will receive multiple doses of the treatment. The study will also collect information on how the body processes the treatment, known as pharmacokinetics. This includes measuring the concentration of CSL889 in the blood at different times. The study aims to provide valuable information on whether CSL889 can be a safe and effective treatment option for managing vaso-occlusive crises in sickle cell disease.
Belgium 
France 
Germany 
Greece 
Italy 
Spain 
The Netherlands